Tesaglitazar ameliorates non-alcoholic fatty liver disease and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient mice

Zhang,Bu-Chun; Li,Wei-Ming; Li,Xian-Kai; Zhu,Meng-Yun; Che,Wen‑Liang; Xu,Ya-Wei

doi:10.3892/etm.2012.713

Tesaglitazar ameliorates non-alcoholic fatty liver disease and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient mice

Authors:
- Bu-Chun Zhang
- Wei-Ming Li
- Xian-Kai Li
- Meng-Yun Zhu
- Wen‑Liang Che
- Ya-Wei Xu
View Affiliations

Affiliations: Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P.R. China
Published online on: September 17, 2012 https://doi.org/10.3892/etm.2012.713
Pages: 987-992

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous research has demonstrated that the dual PPARα/γ agonist tesaglitazar reduces atherosclerosis in a mouse model of hyperlipidemia by reducing both lipid content and inflammation in the aorta. However, much of the underlying mechanism of tesaglitazar in non-alcoholic fatty liver disease (NAFLD) remains less clear. The aim of the present study was to determine whether tesaglitazar attenuates NAFLD and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient (LDLr-/-) mice. Female LDLr-/- mice (3 weeks old) were induced by a high-fat diet (HFD) combined with low-dose streptozotocin (STZ) injection to develop an animal model of type 2 diabetes (T2DM). The mice were randomly divided into two groups: diabetic group (untreated diabetic mice, n=15) and tesaglitazar therapeutic group (n=15, 20 µg/kg/day oral treatment for 6 weeks). Fifteen LDLr-/- mice were fed with an HFD as the control group. Tesaglitazar decreased serum glucose and lipid levels compared with the diabetic mice. Tesaglitazar significantly reduced atherosclerotic lesions, lipid accumulation in the liver, macrophage infiltration, and decreased total hepatic cholesterol and triglyceride content compared to the diabetic mice. In addition, tesaglitazar reduced inflammatory markers at both the serum and mRNA levels. Our data suggest that tesaglitazar may be effective in preventing NAFLD and atherosclerosis in a pre-existing diabetic condition by regulating glucose and lipid metabolism, and the inflammatory response.

View Figures

View References

1	Menghini R, Casagrande V, Menini S, et al: TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. Diabetes. 61:454–462. 2012. View Article : Google Scholar : PubMed/NCBI
2	Scorletti E, Calder PC, Byrne CD, et al: Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine. 40:332–343. 2011. View Article : Google Scholar : PubMed/NCBI
3	Baeck C, Wehr A, Karlmark KR, et al: Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut. 61:416–426. 2012. View Article : Google Scholar
4	Serino M, Menghini R, Fiorentino L, et al: Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes. 56:2541–2546. 2007. View Article : Google Scholar : PubMed/NCBI
5	Wunderlich FT, Ströhle P, Könner AC, et al: Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 12:237–249. 2010. View Article : Google Scholar
6	Hanley AJ, Williams K, Festa A, et al: Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 54:3140–3147. 2005. View Article : Google Scholar : PubMed/NCBI
7	Bieghs V, Rensen PC, Hofker MH and Shiri-Sverdlov R: NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. Atherosclerosis. 220:287–293. 2012. View Article : Google Scholar : PubMed/NCBI
8	Gui T, Shimokado A, Sun Y, et al: Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediators Inflamm. 2012:6930832012.PubMed/NCBI
9	Truman JP, Al Gadban MM, Smith KJ, et al: Differential regulation of acid sphingomyelinase in macrophages stimulated with oxidized low-density lipoprotein (LDL) and oxidized LDL immune complexes: role in phagocytosis and cytokine release. Immunology. 136:30–45. 2012. View Article : Google Scholar : PubMed/NCBI
10	Wouters K, van Gorp PJ, Bieghs V, et al: Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology. 48:474–486. 2008. View Article : Google Scholar
11	Evans JL, Lin JJ and Goldfine ID: Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta. Curr Diabetes Rev. 1:299–307. 2005. View Article : Google Scholar
12	Zandbergen F and Plutzky J: PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta. 1771:972–982. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ciudin A, Hernandez C and Simó R: Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology. Curr Top Med Chem. 12:585–604. 2012. View Article : Google Scholar : PubMed/NCBI
14	Mu J, Woods J, Zhou YP, et al: Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 55:1695–1704. 2006. View Article : Google Scholar : PubMed/NCBI
15	Zadelaar AS, Boesten LS, Jukema JW, et al: Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice. Arterioscler Thromb Vasc Biol. 26:2560–2566. 2006.PubMed/NCBI
16	Chira EC, McMillen TS, Wang S, et al: Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis. 195:100–109. 2007. View Article : Google Scholar
17	Ma KL, Ruan XZ, Powis SH, et al: Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology. 48:770–781. 2008. View Article : Google Scholar : PubMed/NCBI
18	Woollard KJ and Geissmann F: Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 7:77–86. 2010. View Article : Google Scholar : PubMed/NCBI
19	Targher G, Marra F and Marchesini G: Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 51:1947–1953. 2008. View Article : Google Scholar : PubMed/NCBI
20	Bhatia LS, Curzen NP, Calder PC and Byrne CD: Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 33:1190–1200. 2012. View Article : Google Scholar : PubMed/NCBI
21	Kleemann R, Verschuren L, van Erk MJ, et al: Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol. 8:R2002007. View Article : Google Scholar
22	Maina V, Sutti S, Locatelli I, et al: Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Clin Sci (Lond). 122:545–553. 2012. View Article : Google Scholar : PubMed/NCBI
23	Lingrel JB, Pilcher-Roberts R, Basford JE, et al: Myeloid-specific Krüppel-like factor 2 inactivation increases macrophage and neutrophil adhesion and promotes atherosclerosis. Circ Res. 110:1294–1302. 2012.
24	Amar J, Fauvel J, Drouet L, et al: Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J Hypertens. 24:1083–1088. 2006. View Article : Google Scholar : PubMed/NCBI